Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. With a presence in more than 100 countries, we are proud to have reached millions of people with our products.
Amgen’s overall mission is to serve patients, which we consider a privilege.
Amgen gathers and analyses safety data throughout a product’s life cycle. Product safety is rigorously evaluated during the development process through clinical trials. Once a product is approved, safety data collection continues through multiple pathways, including additional clinical studies, reports by patients and health care professionals, registries, scientific literature, and database reviews.
Amgen is committed to providing accurate, up to date and transparent information to patients and their prescribers on all the risk and benefits related to our products. We understand that the ultimate use of the product depends on the individual benefit/risk decision made by patients and their prescribers.
If you wish to contact Amgen for any of the following reasons:
Please call us on +61 2 9870 1333 and provide the details.
Medical Information Line – 1800 803 638
N.B. Some of this information is intended for residents of the U.S. only and is marked accordingly.
Amgen is committed to developing new therapies to treat serious illnesses—a long and careful process. One of the most important steps in this process is the clinical trial where people volunteer to receive an experimental therapy and be observed for its effects.